A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)
Latest Information Update: 17 May 2024
At a glance
- Drugs CEVA 101 (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
Most Recent Events
- 03 May 2024 Results published in the Brain
- 12 Nov 2020 Status changed from active, no longer recruiting to completed.
- 12 May 2020 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.